| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA3538871 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]SCH 534128 assessed as 1 mM BNPP-mediated inhibition of metabolite formation LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | tissue-based format | Scientific Literature | |
| 2. | ALA3538873 | A | Drug metabolism in human recombinant AKR1C2 expressing HEK293 cells treated with 20 uM boceprevir assessed as 100 uM flufenamic acid-mediated inhibition of AKR1C2-mediated metabolite formation after 120 mins in presence of NADPH by LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | cell-based format | Scientific Literature | |
| 3. | ALA3539294 | P | Retention time of the compound by LC-MS/MS method | 23 | ALA3526141 | small-molecule physicochemical format | Scientific Literature | ||
| 4. | ALA3539295 | A | Drug metabolism in human plasma treated with [14C]boceprevir assessed as ratio of drug level by LC-MS/MS method relative to boceprevir | Homo sapiens | 23 | ALA3526141 | cell-free format | Scientific Literature | |
| 5. | ALA3539297 | A | Drug metabolism in human liver microsomes treated with 20 uM [14C]boceprevir assessed as compound formation by LC-MS/FSA method relative to total [14C]boceprevir | Homo sapiens | 21 | ALA3526141 | assay format | Scientific Literature | |
| 6. | ALA3539299 | A | Drug metabolism assessed as human CYP3A4-mediated compound formation from 20 uM [14C]boceprevir after 120 mins by LC-MS/FSA method relative to total [14C]boceprevir | Homo sapiens | 22 | ALA3526141 | single protein format | Scientific Literature | |
| 7. | ALA3539301 | A | Drug metabolism assessed as human CYP3A5-mediated compound formation from 20 uM [14C]boceprevir after 120 mins by LC-MS/FSA method relative to total [14C]boceprevir | Homo sapiens | 22 | ALA3526141 | single protein format | Scientific Literature | |
| 8. | ALA3539302 | A | Drug metabolism assessed as human CYP2D6-mediated compound formation from 5 uM [14C]boceprevir after 120 mins by LC-MS/FSA method relative to total [14C]boceprevir | Homo sapiens | 21 | ALA3526141 | single protein format | Scientific Literature | |
| 9. | ALA3539303 | A | Drug metabolism assessed as human CYP2C19-mediated compound formation from 5 uM [14C]boceprevir after 120 mins by LC-MS/FSA method relative to total [14C]boceprevir | Homo sapiens | 21 | ALA3526141 | single protein format | Scientific Literature | |
| 10. | ALA3539304 | A | Drug metabolism assessed as human CYP21A2-mediated compound formation from 5 uM [14C]boceprevir after 120 mins by LC-MS/FSA method relative to total [14C]boceprevir | Homo sapiens | 22 | ALA3526141 | single protein format | Scientific Literature | |
| 11. | ALA3539305 | A | Drug metabolism assessed as human CYP21A1-mediated compound formation from 5 uM [14C]boceprevir after 120 mins by LC-MS/FSA method relative to total [14C]boceprevir | Homo sapiens | 22 | ALA3526141 | single protein format | Scientific Literature | |
| 12. | ALA3541238 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]SCH 534128 assessed as 1 mM ibuprofen-mediated inhibition of metabolite formation LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | tissue-based format | Scientific Literature | |
| 13. | ALA3541239 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]SCH 534128 assessed as 100 uM diazepam-mediated inhibition of metabolite formation LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | tissue-based format | Scientific Literature | |
| 14. | ALA3541240 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as 2 uM AKR inhibitor ritonavir-mediated metabolite formation after 60 mins co-incubated and pre-incubated with ritonavir by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | tissue-based format | Scientific Literature | |
| 15. | ALA3541241 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]SCH 534128 assessed as 100 uM flufenamic acid-mediated inhibition of metabolite formation LC-MS/MS/FSA method | Homo sapiens | 1 | ALA3526141 | tissue-based format | Scientific Literature | |
| 16. | ALA3541242 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as 2 uM AKR inhibitor ketoconazole-mediated metabolite formation after 60 mins by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | tissue-based format | Scientific Literature | |
| 17. | ALA3541564 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as IC50 for AKR inhibitor diflunisal-mediated metabolite formation after 60 mins by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | tissue-based format | Scientific Literature | |
| 18. | ALA3541565 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as 200 uM AKR inhibitor diflunisal-mediated metabolite formation after 60 mins by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | tissue-based format | Scientific Literature | |
| 19. | ALA3541566 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as IC50 for AKR inhibitor ibuprofen-mediated metabolite formation after 60 mins by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | tissue-based format | Scientific Literature | |
| 20. | ALA3541567 | A | Drug metabolism in human liver cytosol treated with 20 uM [14C]boceprevir assessed as 1000 uM AKR inhibitor ibuprofen-mediated metabolite formation after 60 mins by LC-MS/MS/FSA method | Homo sapiens | 2 | ALA3526141 | tissue-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!